# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Lumos Pharma (NASDAQ:LUMO) reported quarterly losses of $(1.29) per share which missed the analyst consensus estimate of $(1.18...
HC Wainwright & Co. analyst Edward White reiterates Lumos Pharma (NASDAQ:LUMO) with a Buy and maintains $28 price target.
Oppenheimer analyst Leland Gershell maintains Lumos Pharma (NASDAQ:LUMO) with a Outperform and maintains $16 price target.
HC Wainwright & Co. analyst Edward White reiterates Lumos Pharma (NASDAQ:LUMO) with a Buy and maintains $28 price target.
Lumos Pharma (NASDAQ:LUMO) reported quarterly losses of $(1.170) per share which missed the analyst consensus estimate of $(1.1...